AbbVie (ABBV) climbs after raising full-year earnings guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
AbbVie (ABBV) Tops Q2 EPS by 4c, Raises FY Guidance
July 27, 2023 7:39 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $2.91, $0.04 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.87 billion versus the consensus estimate of $13.51 billion.
GUIDANCE:
AbbVie sees FY2023 EPS of $10.90-$11.10, versus the consensus of $10.85.
Raises 2023... MoreAbbVie may see less pain from Humira sales decline as rival lags
July 26, 2023 12:06 PM EDTBy Leroy Leo
(Reuters) - AbbVie Inc is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.
Humira sales are likely to decline when the company reports on Thursday but that would mostly be due to the discounts AbbVie has offered to shield itself from prescription share erosion, analysts have said.
The drugmaker has forecast a 37% drop in Humira sales in 2023 and expects a majority of the hit in the second half... More
AbbVie (ABBV) July weekly option implied volatility elevated into quarter results
July 26, 2023 11:12 AM EDTAbbVie (NYSE: ABBV) July weekly call option implied volatility is at 63, August is at 27; compared to its 52-week range of 16 to 35 into the expected release of quarter results before the bell on July 27.
... MoreAbbVie (ABBV) and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
July 26, 2023 9:04 AM EDTAbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest. This partnership is an expansion of the collaboration AbbVie and Scripps Research formed in 2019 to develop a broad range of potential new and novel therapeutics.
"We've made significant progress to advance rapidly many preclinical and clinical development... More
